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Abstract
Background: South Africa has one of the highest tuberculosis incidence rates. Biologic disease-modifying anti-
rheumatic drugs are associated with an increased risk of tuberculosis. The objective of this study was to describe
the tuberculosis disease incidence rate among public sector patients receiving biologic therapies in the Western
Cape Province.
Methods: A retrospective, descriptive analysis was undertaken using routine health data collated by the Provincial
Health Data Centre from January 2007 (first use of biologic therapy in the Western Cape) to September 2018.
Results: We identified 609 patients treated with tumour necrosis factor-alpha (TNF-α) or non-TNF-α biologic
therapies. Thirty-seven (37) patients developed tuberculosis after biologic therapy exposure, of whom the majority
(78%) had an immune mediated inflammatory disease and the remainder (22%) a haematologic malignancy. The
incidence rate of tuberculosis per 100,000 person-years was 2227 overall [95% confidence interval (CI): 1591, 3037].
Patients treated with TNF-α inhibitors and non-TNF-α inhibitors had estimated incidence rates of 2819 [95% CI:
1669, 4480] and 1825 [95% CI: 1131, 2797], respectively (p = 0.10).
Conclusion: Patients exposed to both TNF-α and non-TNF-α biologic therapies may have a higher incidence of
tuberculosis disease compared to the background risk of 681 cases per 100,000 per year in the Western Cape.
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Background
The efficacy of biologic therapies to treat immune-
mediated inflammatory conditions [1–3] and certain
haematologic malignancies [4, 5] has been established.
Yet the use of biologic therapy is limited by the risk of
opportunistic infections, in particular tuberculosis (TB)
disease [1, 6–13], because it suppresses the immune re-
sponse of the patient to pathogens. This is particularly
relevant given the high background TB incidence in
South Africa, which the World Health Organisation
(WHO) ranks as one of the top TB burden countries
globally with an estimated TB incidence rate of 567 per
100,000 population in 2017 [14].
For these reasons, guidelines recommend screening
and prophylactic therapy for TB prior to initiation of
biologic therapy [8, 15–17]. Biologic therapies specific-
ally targeting tumour necrosis factor-alpha (TNF-α) are
a recognised, independent risk factor for TB disease due
to the central role of TNF-α in granuloma formation
and maintenance [6, 10]. Anti-TNF-α monoclonal anti-
bodies, particularly infliximab and adalimumab, have
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consistently been associated with the highest risk of
developing TB disease [18–23]. Additionally, patients
receiving biologic therapies may have an additional risk
for developing TB due to their underlying disease (in-
flammatory condition or haematological malignancy)
or its treatment including synthetic disease modifying
anti-rheumatic drugs (DMARDs) and corticosteroid
exposure [13, 18].
Current biologic therapy risk estimates for TB have
mostly been assessed in low and intermediate TB burden
countries [8, 20], but not in a high TB burden environ-
ment such as South Africa. The South African Biologics
Registry (SABIO) captures biologic use data for South
African patients receiving private health care, but these
are generally individuals with higher socio-economic
circumstances and lower risk of exposure to TB, and are
not representative of the general South African patient
population. When comparing the TB incidence rates in
TNF-α inhibitors users in the SABIO registry, incidence
was 1387 per 100,000 person-years, which is approximately
10-fold that of the British (BSRBR), French (RATIO) and
Spanish (BIOBADASER) registries where the TB incidence
ranges from 106 to 172 per 100,000 person-years [22, 24].
The Western Cape Province in South Africa has a par-
ticularly high TB burden, with an estimated incidence
rate of 681 per 100,000 population in 2015 [25]. This
study describes the incidence rate and time to TB onset
among public sector patients receiving biologic therapies
in this high-TB burden setting in the Western Cape.
Methods
We conducted a retrospective, descriptive study of anon-
ymised quantitative data from patients who received
biologic therapies in the public health sector in the
Western Cape, South Africa, as identified by the Provin-
cial Health Data Centre (PHDC), a health information
exchange that collates routine health data from a variety
of Provincial health data platforms. The clinical data
were de-identified and underwent data perturbation by
the Provincial Health Data Centre prior to release to
ensure that patients could not be re-identified from their
health records. All patients receiving biologic therapies
in the period from the first recorded biologic use in
January 2007 to 30 September 2018, were included in
the study irrespective of age, therapy type or indication.
The biologic therapies included the TNF-α inhibitors
infliximab, adalimumab, golimumab and etanercept, and
the non-TNF-α inhibitor biologics rituximab, abatacept,
tocilizumab and ustekinumab.
We analysed the following variables: baseline charac-
teristics (age, gender, HIV status, dispensed isoniazid
preventative therapy (IPT) and use of traditional DMAR
DS), biologic exposure (therapy type, treatment duration
and any biologic swops) and outcome variables (TB
disease diagnosis).
In South Africa an established IPT protocol exists for
HIV positive patients only [26]. A 12-month duration of
IPT is recommended in all non-pregnant HIV positive
patients who screened negative for active TB based on
symptoms, irrespective of their latent TB status. There is
no formal IPT protocol for patients with rheumatologic
or haematologic conditions.
The indications for biologic therapy were broadly
grouped into immune-mediated inflammatory diseases
(including rheumatoid arthritis, spondyloarthropathies
and juvenile idiopathic arthritis) and haematologic
malignancy, (including Non-Hodgkin Lymphoma and
chronic lymphoid leukaemia) based on the combination
of traditional DMARD or chemotherapeutic use. A
rheumatologist (HR) led the classification process where
dispensing records of traditional DMARDs (methotrex-
ate, sulfasalazine and/ or chloroquine) in combination
with any of the eight biologic therapies was classified as
an immune mediated inflammatory disease (IMID). On
the other hand, dispensing record of chemotherapeutic
medications (cyclophosphamide, doxorubicin and/ or
vincristine) in combination with rituximab use was clas-
sified as a haematologic malignancy.
Ascertainment of TB was based on digital health
records compiled by the PHDC using the data from the
National Health Laboratory Services, pharmacy dispens-
ing records from the Western Cape Government Health
electronic platform, and data from the electronic TB
register (ETR).
Statistical analysis was undertaken using SPSS version
25.0 [27]. Categorical and numerical baseline variables
were compared between therapy (TNF-α and non-TNF-
α inhibitors) and indication groups (IMID and haemato-
logic malignancy) using Chi-Square and Mann-Whitney
U test respectively. Normality of distribution was tested
using both Kolmogorov-Smirnov and Shapiro-Wilk tests.
Incidence rates of TB were expressed as events per 100,
000 person-years using OpenEpi online statistical calcu-
lator with Mid-P exact 95% confidence intervals (CI)
[28]. The total, two indication groups (immune mediated
inflammatory diseases and haematologic malignancy),
two major therapy groups (TNF-α and non-TNF-α in-
hibitors) and individual biologic therapy incidence rates
were calculated. Some patients were on multiple biologic
therapies, therefore proportions and individual biologic
therapy TB incidence rates were calculated based on the
most recent biologic therapy used before or at the time
of TB diagnosis. The median time to TB disease
(expressed in months) from the start of the most recent
biologic therapy used was estimated overall and for the
individual biologic therapies. The relationship between
time to developing TB and risk factors was modelled
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using Cox proportional hazards models. The data met
proportional hazards assumptions. Independent associ-
ation of predictor variables for TB incidence were esti-
mated as adjusted hazard ratios and 95% CI.
Results
During the study period, 611 patients received biologic
therapies of which 609 patients were included in the
study. One patient was excluded due to the date of death
occurring prior to the date of ascertainment of TB, most
likely indicating the lag time for TB culture from a
sample taken just before death. A second patient was
excluded based on a highly implausible combination of
dispensed medications, which was likely an uncorrected
dispensing record error.
The baseline variables, including age, gender, HIV
status and isoniazid preventative therapy (IPT) are
compared between indication and therapy groups as
illustrated in Table 1. Of note, the significant differences
in baseline characteristics between the two therapy
groups were age, patients treated with TNF-α were
younger than those treated with non-TNF-α inhibitors.
Further, more males were treated with TNF-α and
females with non-TNF-α inhibitors. Significantly more
patients treated with TNF-α inhibitors received IPT
compared to patients treated with non-TNF-α inhibitors.
Regarding the indication groups, significant differences
were also observed between age groups, where patients
with an IMID were younger than patients with a haem-
atologic malignancy. Significantly more patients with
IMID received IPT than patients with haematologic ma-
lignancies. The outcome variables, TB and death, are
also illustrated in Table 1. Significantly more patients
who were treated with non-TNF-α inhibitors compared
to TNF-α inhibitors, and who had a haematological ma-
lignancy compared to IMID, died in this study period.
Of the 609 patients, 37 patients developed TB follow-
ing initiation of biologic therapy. Four patients had two
TB episodes, therefore a total of 41 TB episodes were
observed in the study period. The total follow-up time
to developing TB disease, death or study end date was
1662 person-years with a calculated TB incidence rate of
2227 per 100,000 person-years [95% CI: 1591, 3037]. Of
the 37 cases, 29 and 8 patients with an IMID and haem-
atologic malignancy, respectively, developed TB disease.
The total follow-up time was 1084 and 558 person-years
for the IMID and haematologic malignancy indication
groups, respectively. Thus, the incidence rate per 100,
000 person-years was higher in the IMID group, 2676
[95% CI: 1826, 3793], compared to the haematologic
Table 1 Baseline and outcome variables by therapy and indication groups
All patients n = 609 n (%) Therapy groups n = 598a Indication groups n = 609
TNF-α n = 174 n (%) Non-TNF-α n = 424
n (%)
pb IMID n = 348 n (%) HM n = 261 n (%) p
AGE IN YEARS at initiation of biologic therapy
Median (IQR) 41 (22–57) 33 (18–46) 47 (25–59) < 0.001 28 (13–45) 55 (41–63) < 0.001
GENDER
F 311 (51) 73 (42) 232 (55) 0.005 185 (53) 126 (48) 0.223
M 298 (49) 101 (58) 192 (45) 163 (47) 135 (52)
HIV STATUS at initiation of therapy
positive 45 (7) 13 (8) 31 (7) 0.946 27 (8) 18 (7) 0.687
negative 564 (93) 161 (92) 393 (93) 321 (92) 243 (93)
IPT
yes 211 (35) 119 (78) 83 (20) < 0.001 206 (59) 5 (2) < 0.001
no 398 (65) 55 (22) 341 (80) 142 (41) 256 (98)
SURVIVAL at end of study period
died 94 (15) 16 (9) 78 (18) 0.005 39 (11) 55 (21) 0.001
alive 515 (85) 158 (91) 346 (82) 309 (89) 206 (79)
TB INCIDENCE after initiation of biologic therapy
TB 37 (6) 16 (9) 19 (4) 0.026 29 (8) 8 (3) 0.007
no TB 572 (94) 158 (91) 405 (96) 319 (92) 253 (97)
apatients receiving both TNF-α and non-TNF-α inhibitors (n = 11) were excluded
bp value compares TNF-α to non-TNF-α only (n = 598) using a Mann-Whitney test for age in years and Chi-Square tests for categorical variables
TNF-α tumour necrosis factor-alpha inhibitors, non-TNF-α non-tumour necrosis factor- alpha inhibitors, IMID immune mediated inflammatory disease, HM
haematologic malignancy, IPT isoniazid preventative therapy
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malignancy group, 1434 [95% CI: 666, 2723]. Although
the incidence rate ratio was 1.87 [95% CI: 0.83, 4.72], it
was not statistically significant (p = 0.06).
The overall, indication and therapy group TB inci-
dence rates are illustrated in Fig. 1. Of the 37 TB disease
patient cases, 16 and 19 occurred in patients who were
exclusively exposed to TNF-α inhibitors and non-TNF-α
inhibitors, respectively. Two patients were exposed to a
combination of TNF-α and non-TNF-α biologic therap-
ies and were therefore excluded from the therapy
groups’ incidence rate calculation. The total follow-up
time was 568 and 1041 person-years for the TNF-α and
non-TNF-α inhibitor groups, respectively. The incidence
rate of TB was higher in the TNF-α inhibitor group,
2819 [95% CI: 1669, 4480], compared to non-TNF-α in-
hibitor group, 1825 [95% CI: 1131, 2797]. Although the
incidence rate ratio was 1.54 [95% CI: 0.74, 3.17], it was
not statistically significant (p = 0.10).
The TB incidence rates per biologic therapy are illus-
trated in Fig. 2. The TB disease incidence rates per indi-
vidual biologic therapy were calculated based on the
most recent biologic therapy used before or at the time
of TB disease episode (n = 41) divided by the sum of
total cohort person-years for each biologic therapy.
Incidence rates per 100,000 person-years were highest
for rituximab, 12,830 [95% CI: 8055, 19,460] followed by
golimumab, 12,260 [95% CI: 2056, 40,510] and inflixi-
mab, 11,550 [95% CI: 6072, 20,070]. Lower rates of 3619
[95% CI: 181, 17,850], 2997 [95% CI: 952, 7230] and
2590 [95% CI: 659, 7049] were estimated for tocilizumab,
adalimumab and etanercept, respectively. Although the
TB disease incidence rate was highest for rituximab, it was
only significantly higher when compared to adalimumab
(p = 0.003) and etanercept (p = 0.004), not when compared
to the other biologic therapies. There were no TB episodes
during or subsequent to abatacept or ustekinumab treat-
ment in this study population.
The overall median time to development of TB dis-
ease was 8.3 months. (Table 2) The median time to TB
was 19 and 7.4 months for patients exposed to TNF-α
and non-TNF-α inhibitors, respectively. The lowest
median time to TB was in patients most recently
exposed to golimumab (4.8 months), followed by ritux-
imab (7.1 months) and adalimumab (12.6 months).
Estimated median times to TB disease were greater in
etanercept (33.8 months), infliximab (27.7 months) and
tocilizumab (15.0 months).
A Cox proportional hazard model assessed the impact
of several baseline characteristics on the time to TB inci-
dence, as shown in Table 3. Of the variables included in
Fig. 1 Incidence rates with 95% CI of tuberculosis disease per biologic therapies, indication and therapy groups. CI = confidence interval; IMID =
immune mediated inflammatory disease; TNF-α = tumour necrosis factor-alpha
Fig. 2 Incidence rates with 95% confidence intervals of tuberculosis disease per individual biologic therapies
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the model, only a positive HIV status at biologic treat-
ment initiation significantly contributed to development
of TB (p = 0.01).
Discussion
We estimated the incidence of TB disease in public
health sector patients exposed to biologic therapies in
South Africa, Western Cape. We found that the estimated
incidence rate among biologic therapy users was higher
compared to previously published literature [22, 24].
When comparing estimated tuberculosis disease incidence
rates to the estimated background incidence rate of 681
cases per 100,000 per year in the Western Cape [25], the
estimated risk of tuberculosis disease is 3.3 fold higher
overall, and is 4.1-fold and 2.7-fold higher than back-
ground incidence rates in TNF-α and non-TNF-α biologic
therapies respectively.
Furthermore, our findings show higher incidence rates
than previous local and international biologic registry
findings. Our estimated TB disease incidence in patients
exposed to biologic therapies (2227 per 100,000 person-
years) was 1.8-fold higher than the South African Bio-
logics Registry (SABIO) incidence rate (1240 per 100,000
person-years) [24]. This difference could be explained by
both different geographical regions and socio-economic
circumstances, where only the Western Cape public
health sector was included in this study and majority
private health sector patients throughout South Africa in
the SABIO registry. International registry data, including
British (BSRBR), French (RATIO) and Spanish (BIOBA-
DASER), focused primarily on TNF-α inhibitors where
estimated incidence rates varied from 106 to 172 per
100,000 person-years [22, 24]. Our estimated TB disease
incidence rate among patients exposed to TNF-α inhibi-
tors (2819 per 100,000 person-years) was therefore 16 to
27-fold higher. We hypothesise that our finding of a
higher TB disease incidence rate may be a consequence
of higher background TB disease risk. We found that the
Table 2 Number of tuberculosis episodes and time to tuberculosis disease, by individual biologic therapy
Biologic therapies Total no of
patients treateda
No of TB episodes b
(% of TB episodes/
total treated) c
Time to TB (months) d
Median (IQR)
All biologics – 41 8.30 (3.67–27.70)
TNF-α inhibitors 209 20 18.95 (5.08–32.79)
adalimumab 48 4 (8.3%) 12.56 (3.20–18.90)
etanercept 49 3 (6.1%) 33.84 (12.59–46.82)
golimumab 12 2 (16.7%) 4.82 (4.33–5.31)
infliximab 100 11 (11.0%) 27.70 (3.64–39.02)
Non-TNF-α inhibitors 441 21 7.43 (2.83–16.24)
abatacept 4 0 –
rituximab 418 20 (4.8%) 7.08 (2.48–18.02)
tocilizumab 18 1 (5.6%) 15.02 (15.02–15.02)
ustekinumab 1 0 –
atotal number of patients exposed to a biologic therapy at any point in study period (one patient may be exposed to multiple biologic therapies)
bnumber of tuberculosis episodes (single or multiple) per patient according to the most recent biologic therapy used before or at the time of tuberculosis disease
diagnosis (n = 41).
cpercentage of tuberculosis disease episodes (based on most recent biologic therapy used) per total number of patients exposed to a biologic therapy.
dtime to tuberculosis disease in months from the start of the most recent or current biologic used to the date of tuberculosis disease diagnosis.
TB tuberculosis, TNF-α tumour necrosis factor-alpha, min minimum, max maximum, IQR interquartile range
Table 3 Cox proportional hazard model for variables associated with TB disease
p-value Hazard ratio [95% CI]
Age in years 0.35 1.009 [0.990–1.029]
Gender (female compared to male) 0.48 1.283 [0.641–2.570]
HIV status (HIV+ compared to HIV-) 0.01 3.000 [1.262–7.127]
IPT (IPT compared to no IPT) 0.32 1.524 [0.665–3.493]
Indication groups (IMID compared to HM) 0.42 1.568 [0.523–4.698]
Therapy groups (TNF-α inhibitors compared to non-TNF-α inhibitors) 0.62 1.233 [0.543–2.801]
IPT isoniazid preventative therapy, IMID immune mediated inflammatory disease, HM haematologic malignancy, TNF-α tumour necrosis factor-alpha
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TB disease incidence rate ratio is 1.54 when comparing
TNF-α to non-TNF-α inhibitors, which was in keeping
with the findings of others [9, 10, 18].
Interestingly, the highest TB disease incidence rate for an
individual biologic therapy was estimated in rituximab, a B-
cell depleting agent, although its incidence rate was only
significantly higher when compared to adalimumab and
etanercept. Due to the mechanism of action, rituximab has
been assumed to be the biologic with the lowest TB risk,
and this has previously been supported by robust evidence
[8, 9, 19]. Rituximab was the most commonly used biologic
in this study (418 of 609 patients had rituximab exposure).
A likely explanation for the high rituximab-associated TB
incidence rate is the different patient profile, including
patients with haematologic malignancy which poses an in-
trinsic risk for developing TB disease due to concomitant
chemotherapy and inherent immune compromise [29].
Furthermore, we found that patients with haematologic
malignancy do not routinely receive latent TB screening
and isoniazid preventative therapy (IPT) in the Western
Cape. In our study the overwhelming majority (98%) of
patients with a haematologic malignancy did not re-
ceive IPT (illustrated in Table 1). Only 20% of patients
exposed to a non-TNF-α inhibitor (of which rituximab
was most frequently used) received IPT which could
contribute to the high TB incidence rate estimated in
rituximab exposed patients. A positive HIV status is a
further confounder as four of the 19 (21%) TB positive
patients who were exposed to rituximab were also HIV
positive. Our findings of estimated median time to TB
disease was not in keeping with previously published
literature, where infliximab typically has the shortest
time to TB event [20, 30, 31].
Our study has several limitations. Firstly, the PHDC col-
lects routine clinical data to inform clinical care. It is not
primarily a research data source and not all TB-related
diagnostic and treatment parameters are captured digitally
for individual patients. For example, the date of first TB
disease evidence was inferred from the treatment start
date rather than onset of symptoms, which may indicate
that a diagnosis was made clinically but not captured
electronically. Thus, time to development of TB may be
prolonged and variable. Causes of death data were also
not recorded in the PHDC. Secondly, this study has a
smaller sample size (n = 609) compared to other studies
and biologic registries [22, 24]. Moreover, four or less TB
disease episodes occurred following the use of adalimu-
mab, etanercept, golimumab and tocilizumab, respectively,
which limits the ability to calculate TB disease incidence
rates for individual biologic therapies and median time to
TB diagnosis. Survival analysis could not be done by indi-
vidual biologic therapy as patients frequently changed be-
tween and were exposed to multiple biologic therapies.
Thirdly, our findings were compared to the background
TB incidence where the risk was estimated per 100,000
population in the general population [25], whereas we
estimated incidence rates in the population exposed to
biologic therapies. In addition, when comparing our find-
ings to other geographical areas we could only compare
incidence rates in exposed patients, without considering
the baseline TB risk as data on incidence rates in the gen-
eral population were not available. These crude compari-
sons with local and international findings should therefore
not be overinterpreted. Lastly, we could not accurately
assess all confounders for TB risk such as which patients
were assessed for IPT and the exact underlying biologic
therapy indication. Specific diagnoses, such as indication
for biologic therapy, was not available due to limited re-
cording of International Classification of Diseases (ICD)
codes in electronic health data. Future research should ac-
count for all TB disease risk factors and establish the indi-
cation for biologic therapy, and should be undertaken
when the number of patients receiving biologic therapy
has increased substantially. Ideally a more robust study
design analysing prospective data should be employed to
estimate causal relationships.
Conclusion
We found higher TB incidence rates in Western Cape
public sector patients exposed to both TNF-α and non-
TNF-α inhibitor biologic therapies compared to the
background risk. The overall TB incidence rate found in
patients receiving biologic therapy in this study are gen-
erally substantially higher (estimated at approximately
3.3 fold) than incidence rates that have been reported
for the Western Cape previously [25]. Due to their
established efficacy, biologic therapies will become more
accessible and affordable for patients accessing public
health services in South Africa. It is therefore imperative
to evaluate the safety profile of biologic therapies in this
setting, particularly their impact on the risk of active TB
infection. Latent TB screening and preventive treatment
among patients exposed to biologic therapies should
thus be emphasized in treatment protocols.
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